Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 709

The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.

Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies

Open access
Doria-Rose, Nicole A., Schramm, Chaim A., Gorman, Jason, Moore, Penny L., Bhiman, Jinal N., DeKosky, Brandon J., Ernandes, Michael J., Georgiev, Ivelin S., Kim, Helen J., Pancera, Marie, Staupe, Ryan P., Altae-Tran, Han R., Bailer, Robert T., Crooks, Ema T., Cupo, Albert, Druz, Aliaksandr, Garrett, Nigel J., Hoi, Kam H., Kong, Rui, Louder, Mark K., Longo, Nancy S., McKee, Krisha, Nonyane, Molati, O’Dell, Sijy, Roark, Ryan S., Rudicell, Rebecca S., Schmidt, Stephen D., Sheward, Daniel J., Soto, Cinque, Wibmer, Constantinos Kurt, Yang, Yongping, Zhang, Zhenhai, NISC Comparative Sequencing, Mullikin, James C., Binley, James M., Sanders, Rogier W., Wilson, Ian A., Moore, John P., Ward, Andrew B., Georgiou, George, Williamson, Carolyn, Abdool Karim, Salim S., Morris, Lynn, Kwong, Peter D., Shapiro, Lawrence, Mascola, John R.·2014·Nature

Abstract

Antibodies capable of neutralizing HIV-1 often target variable regions 1 and 2 (V1V2) of the HIV-1 envelope, but the mechanism of their elicitation has been unclear. Here we define the developmental pathway by which such antibodies are generated and acquire the requisite molecular characteristics for neutralization. Twelve somatically related neutralizing antibodies (CAP256-VRC26.01–12) were isolated from donor CAP256 (from the Centre for the AIDS Programme of Research in South Africa (CAPRISA)); each antibody contained the protruding tyrosine-sulphated, anionic antigen-binding loop (complementarity-determining region (CDR) H3) characteristic of this category of antibodies. Their unmutated ancestor emerged between weeks 30–38 post-infection with a 35-residue CDR H3, and neutralized the virus that superinfected this individual 15 weeks after initial infection. Improved neutralization breadth and potency occurred by week 59 with modest affinity maturation, and was preceded by extensive diversification of the virus population. HIV-1 V1V2-directed neutralizing antibodies can thus develop relatively rapidly through initial selection of B cells with a long CDR H3, and limited subsequent somatic hypermutation. These data provide important insights relevant to HIV-1 vaccine development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nature13036

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 83 references

Cited by

See all 709

Metadata

Authors
Doria-Rose, N. A., Schramm, C. A., Gorman, J., Moore, P. L., Bhiman, J. N., DeKosky, B. J., Ernandes, M. J., Georgiev, I. S., Kim, H. J., Pancera, M., Staupe, R. P., Altae-Tran, H. R., Bailer, R. T., Crooks, E. T., Cupo, A., Druz, A., Garrett, N. J., Hoi, K. H., Kong, R., Louder, M. K., Longo, N. S., McKee, K., Nonyane, M., O’Dell, S., Roark, R. S., Rudicell, R. S., Schmidt, S. D., Sheward, D. J., Soto, C., Wibmer, C. K., Yang, Y., Zhang, Z., Sequencing, N. C., Mullikin, J. C., Binley, J. M., Sanders, R. W., Wilson, I. A., Moore, J. P., Ward, A. B., Georgiou, G., Williamson, C., Abdool Karim, S. S., Morris, L., Kwong, P. D., Shapiro, L., & Mascola, J. R.
Venue
Nature
Published
2014-03-02
Volume
509
Issue
7498
Pages
55-62
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2010959676
Cited by
709
References
83
FWCI
44.62
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. https://app.cochat.ai/papers/10.1038/nature13036
The paper
Doria-Rose, N. A., Schramm, C. A., Gorman, J., Moore, P. L., Bhiman, J. N., DeKosky, B. J., Ernandes, M. J., Georgiev, I. S., Kim, H. J., Pancera, M., Staupe, R. P., Altae-Tran, H. R., Bailer, R. T., Crooks, E. T., Cupo, A., Druz, A., Garrett, N. J., Hoi, K. H., Kong, R., . . . Mascola, J. R. (2014). Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. https://doi.org/10.1038/nature13036

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.